Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut (NASDAQ:COLL)

seekingalpha.com · 2026-10-17

Collegium Pharmaceutical is rated a Buy after a guidance cut and stock drop, with the market pricing in an overly pessimistic scenario. Click for more on COLL.

TickrTrends take: Collegium Pharmaceutical trades at a multiple below 3 times its cash earnings, a metric that TickrTrends currently identifies as undervalued for this Healthcare sector company. The recent guidance reduction suggests investors should monitor whether the company can maintain its cash generation capability going forward, as earnings quality becomes more important at lower valuation multiples. Readers focused on valuation should track whether management's revised outlook stabilizes or indicates deeper operational challenges that could pressure the cash earnings multiple higher.

Read the full story at seekingalpha.com →